NEW YORK (GenomeWeb News) – Applied BioCode today said it has signed a license and supply agreement covering its barcoded magnetic bead (BMB) technology with molecular diagnostics firm Genetic Analysis.
The deal, which covers in vitro diagnostic and life science research applications, gives Genetic Analysis access to BMB patents and BioCode analyzers for molecular diagnostic testing of microbial imbalances in the gastrointestinal tract. Further details of the agreement were not disclosed.
Genetic Analysis, based in Oslo, Norway, launched its first product, the GA-map IBS Dysbiosis Test in October. GA-map is a DNA-based platform technology that allows for the simultaneous analysis of a large number of similar gene fragments in one reaction, it said on its website.
"Our barcoded magnetic beads and BioCode multiplex analyzers along with Genetic Analysis's GA-map IBS Dysbiosis Test will enable researchers and healthcare providers access to new ways to address this sometime[s] debilitating disease," Applied BioCode President Winston Ho said in a statement.